Plant-based myostatin regulator for muscle and metabolic health
A GRAS-listed, plant-based ingredient designed to reduce myostatin, increase endurance, and help preserve muscle mass. The low-dose, calorie-free, water-soluble, taste-neutral format supports integration into functional beverages and powders. Human clinical evidence reports reductions in myostatin and improvements in endurance, including effects in aging adults and GLP-1 users.
Overview
A plant-based ingredient designed to enhance muscle and metabolic health by targeting the biological root of muscle atrophy. Rather than relying on protein-based approaches, it reduces myostatin levels, a protein associated with muscle breakdown, by 36.2% as demonstrated in a U.S.-based human clinical trial. The ingredient is reported to increase endurance by 37% and to help preserve muscle mass in aging adults and GLP-1 users. Its delivery is low-dose, calorie-free, and water-soluble, making it suitable for integration into functional beverages and powders.
Technical specifications
- Active mechanism: Activates TRPV3 ion channels and stimulates mitochondrial biogenesis to combat muscle atrophy.
- Format: Low-dose, calorie-free, water-soluble, and taste-neutral, suitable for beverages and powder applications.
- Commercial production: Already in-market in Canada as an NHP with GMP-compliant, scalable production capabilities.
- Clinical validation: Supported by human and animal trials, demonstrating significant reductions in serum myostatin and improvements in endurance.
Technology readiness level
Technology Readiness Level 9, indicating it is fully market-ready. It is currently available in the Canadian market and prepared for integration into commercial food and beverage products.
About Veos Pharmaceuticals
Veos Pharmaceuticals is a Madrid-based biotechnology company that develops and commercializes science-backed solutions across human health, agriculture, and environmental sustainability. Founded in 2023, the company operates as a vertically integrated entity, maintaining direct control over research, formulation, regulatory compliance, and distribution across Europe and North America. Its platform-based innovation model is built on scientific rigor and commercial discipline, resulting in a portfolio of more than 40 commercial products. By combining internal R&D with selective in-licensing and strategic partnerships, Veos translates validated research into scalable, real-world applications. The firm distinguishes itself through its focus on profitability, which it has maintained since 2024, and its commitment to manufacturing standards, leveraging European facilities to ensure quality and regulatory adherence.
The company's work provides critical value to diverse stakeholders, including patients, clinicians, growers, and industrial partners. Its human health platform delivers pharmaceutical and nutraceutical products targeting areas such as ophthalmology and muscle health, while its agricultural and environmental platforms focus on enhancing crop resilience, water treatment, and material recovery. Through its direct-to-consumer and business-to-business channels, Veos addresses specific market needs with evidence-based technologies. The company’s growth is supported by a senior leadership team with extensive expertise in pharmaceutical operations and biotechnology, and it actively collaborates with research institutions and global distributors to expand the deployment and impact of its technologies.
Inquire about this partnering listing
Industry applications
delivered to your inbox.